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BACKGROUND. Cross-reactive immunological material–negative (CRIM-negative)
infantile Pompe disease (IPD) patients develop an immune response against enzyme
replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic
immune tolerance induction (ITI) with rituximab, methotrexate, and IVIG successfully
prevents development of deleterious rhGAA IgG antibodies; however, safety, likelihood of
success, and long-term efficacy of ITI in a larger cohort remain unknown.
METHODS. Clinical data were analyzed for 19 CRIM-negative IPD patients who received
ITI with rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared
to a historical cohort of 10 CRIM-negative IPD patients on ERT monotherapy.
RESULTS. ITI was safely tolerated, although infections were reported in 4 patients.
Fourteen (74%) ERT+ITI patients were alive, with a median age of 44.2 months at their final
assessment. The eldest survivor was 103.9 months old, with 100.2 months of follow-up after
initiation of ERT+ITI. Death (n = 5) occurred at a median age of 29.2 months and was
unrelated to the administration of ITI. Fifteen patients either did not seroconvert (n = 8) or
maintained low titers (n = 7; defined as titers of ≤6,400 throughout the course of ERT)
following ERT+ITI. […]
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BACKGROUND. Cross-reactive immunological material–negative (CRIM-negative) infantile Pompe 
disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) 
with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) 
with rituximab, methotrexate, and IVIG successfully prevents development of deleterious rhGAA 
IgG antibodies; however, safety, likelihood of success, and long-term efficacy of ITI in a larger cohort 
remain unknown.
METHODS. Clinical data were analyzed for 19 CRIM-negative IPD patients who received ITI with 
rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared to a historical 
cohort of 10 CRIM-negative IPD patients on ERT monotherapy.
RESULTS. ITI was safely tolerated, although infections were reported in 4 patients. Fourteen (74%) 
ERT+ITI patients were alive, with a median age of 44.2 months at their final assessment. The eldest 
survivor was 103.9 months old, with 100.2 months of follow-up after initiation of ERT+ITI. Death (n 
= 5) occurred at a median age of 29.2 months and was unrelated to the administration of ITI. Fifteen 
patients either did not seroconvert (n = 8) or maintained low titers (n = 7; defined as titers of ≤6,400 
throughout the course of ERT) following ERT+ITI. Only one patient developed high and sustained 
antibody titers (defined as titers of ≥51,200 at or beyond 6 months on ERT). Left ventricular mass 
index (LVMI) decreased from a median of 248.5 g/m2 at baseline to 76.8 g/m2 at a median time 
from ERT+ITI initiation to 59 weeks. ERT+ITI significantly improved overall survival (P = 0.001), 
eliminated/reduced antibodies at values of ≤6,400 at week 52 on ERT (P = 0.0004), and improved 
LVMI at week 52 on ERT (P = 0.02) when compared with ERT monotherapy.
CONCLUSION. Evidence from this international cohort of CRIM-negative IPD patients further 
supports the safety, feasibility, and efficacy of ITI in the prevention of immune responses to ERT.
TRIAL REGISTRATION. Clinicaltrials.gov NCT01665326.
FUNDING. This research was supported in part by the Lysosomal Disease Network, a part of NIH Rare 
Diseases Clinical Research Network, and by a grant from Genzyme, a Sanofi company.
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Introduction
The approval of  insulin in 1982 as the first recombinant therapeutic protein marked the emergence 
of  a new therapeutic era in which proteins, such as enzymes, hormones, cytokines, monoclonal anti-
bodies, and toxins were approved to treat human disease. Despite this success, one of  the challenges 
faced with administration of  therapeutic proteins is the potential to elicit an immune response, which 
may directly affect safety and efficacy. Antibodies that develop against a therapeutic protein may alter 
its pharmacokinetic profile, diminish its pharmacodynamics, and compromise clinical benefits (1–6). 
Pompe disease (OMIM # 232300, glycogen storage disease II) is an autosomal recessive lysosomal 
storage disorder treated via enzyme replacement therapy (ERT) with recombinant human acid α-glu-
cosidase (rhGAA, alglucosidase alfa), a treatment that has faced significant challenges posed by its 
immunogenicity in this patient population (2, 7). Variants in the GAA gene lead to deficiency of  acid 
α-glucosidase (GAA, α-1, 4-glucosidase), resulting in progressive accumulation of  lysosomal glycogen, 
particularly in skeletal, cardiac, and smooth muscle tissues. Classical infantile Pompe disease (IPD), 
the most severe presentation, results in death secondary to cardiorespiratory failure within the first 2 
years of  life, if  untreated (8).
ERT with rhGAA, currently the only FDA-approved treatment available for Pompe disease, has 
prolonged survival and improved clinical outcomes in patients with IPD (9–11). However, administra-
tion of  rhGAA triggers an immune response in some patients, particularly those with 2 null GAA vari-
ants that cause complete absence of  endogenous GAA on Western blot (2, 12) and are characterized 
as cross-reactive immunological material (CRIM) negative. The development of  high and sustained 
rhGAA IgG antibody titers (HSAT; defined as titers of  ≥51,200 at or beyond 6 months on ERT) or 
sustained intermediate titers (SIT; defined as titers of  ≥12,800 and <51,200 within first year on ERT) 
is associated with subsequent clinical decline and death in patients with IPD, despite ongoing ERT (2, 
13). Antibody-mediated reduction/diversion of  active rhGAA to/from muscle tissues likely accounts 
for this therapeutic failure. Pharmacokinetic studies of  ERT-treated patients with IPD demonstrated 
an average increase in clearance of  infused rhGAA by 50% from week 1 to week 12 in patients with 
rhGAA IgG antibody titers of  ≥12,800 at week 12 (14).
Various approaches to prevent the development of  rhGAA IgG antibody production in patients 
with Pompe disease in clinical and preclinical settings have been attempted, including a protocol with 
rituximab and sirolimus or mycophenolate, synthetic vaccine particles that contain only rapamycin, 
and anti-CD4 antibodies (15–20). The implementation of  immune tolerance induction (ITI) using a 
combination of  rituximab, methotrexate, and/or intravenous immunoglobulin (IVIG) infusions has 
been safely tolerated and effective in preventing the development of  deleterious rhGAA IgG antibodies 
when administered in the ERT-naive and early ERT setting in patients with CRIM-negative IPD (21–
23). While implementation of  ITI prior to initiation of  ERT is ideal, patients who had received ITI 
after initiation of  ERT and prior to the development of  HSAT successfully tolerated ITI but required 
prolonged administration of  rituximab, methotrexate, and IVIG infusions (22). Various combinations 
of  rituximab, cyclophosphamide, IVIG, plasmapheresis, and increased doses of  ERT have been tried 
without success in patients with IPD who developed HSAT prior to implementation of  ITI. ITI (ritux-
imab, methotrexate, and/or IVIG) with the addition of  bortezomib, which targets antibody-secreting 
plasma cells, successfully reduced antibody titers and stabilized clinical decline in at least 4 patients, as 
previously published (24–26). However, such a “rescue” approach is not ideal, due to prolonged immu-
nosuppression arising from the use of  maintenance doses of  rituximab and methotrexate along with 
bortezomib compared to a shorter 5-week course of  ITI administered in an ERT-naive setting (26).
The administration of  ITI in the ERT-naive setting has become the standard of  care and optimal 
approach in treating patients with CRIM-negative IPD (27). We previously reported the successful imple-
mentation of  ITI using rituximab, methotrexate, and IVIG in the first cohorts of  CRIM-negative IPD 
patients on 2 and 9 patients who received ITI in the early ERT and ERT-naive settings, respectively (22, 
23). The purpose of  this study was to evaluate the long-term safety of  prophylactic ITI in the ERT-na-
ive setting (ERT+ITI) in a larger cohort. In addition, the effectiveness of  ERT+ITI for CRIM-negative 
ERT-naive patients with IPD was compared to a historical cohort of  CRIM-negative IPD patients on 
ERT monotherapy with regards to improvement in survival, prevention of  rhGAA IgG antibody devel-
opment, and reduction in left ventricular mass index (LVMI [g/m2]).
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Results
Patient and ITI treatment details
Of the entire IPD cohort of  217 patients, 68 were identified as CRIM negative (31%), based on Western 
blot and/or mutation status, as previously described (28). Of  the 68 CRIM-negative patients, 19 fulfilled 
all inclusion criteria for the present study. The 10 CRIM-negative patients on ERT monotherapy used as a 
comparator group (described later) were a subset of  these 68 patients. These CRIM-negative patients have 
been used as a comparator group in the earlier publications and, hence, for consistency the same group 
was used (2, 12, 23). Patient demographics are presented in Tables 1 and 2, and the GAA variant data are 
presented in Supplemental Table 1 (supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.94328DS1). Thirty-eight GAA variants were identified, consisting of  twenty-three 
(60.5%) nonsense, twelve (31.5%) frameshift, and 3 (8.0%) splice-site variants. Nearly half  of  the identified 
GAA variants (n = 17, 45%) were the common African American c.2560C>T variant. Two GAA variants 
(c.1292_1295dupTGCA and c.437delT) were novel, likely pathogenic variants not previously described 
(29, 30). The median age at diagnosis was 2.6 months (range 0.0–9.8 months), and median age at initiation 
of  ERT+ITI was 3.4 months (range 0.1–10.9 months) (Tables 1 and 2). The median duration of  data col-
lection was 24.2 months since initiation of  ERT+ITI (range 6.0–100.2 months).
Fourteen of the nineteen patients received one cycle of ITI and were off ITI medications for a median time 
of 32.9 months, with the longest duration being 99.2 months. The remaining 5 patients (patients 7, 8, 10, 12, 
and 15) received more than one cycle of ITI. Despite maintaining low antibody titers, patient 10 received main-
tenance rituximab every 2 to 3 months following ERT+ITI for 32 months. He has now been off all ITI medica-
Table 1. Demographics of CRIM-negative IPD patients living at the time of database lock and treated with ERT+ITI in the ERT-naive 
setting
Patient Sex Race/ethnicity Age at diagnosis (mo) Age at initiation of ERT (mo) Current age (mo)
1 F European descent 1.9 3.7 103.9
3 F Hispanic 2.5 3.0 67.7
4 M African American 3.5 4.5 66.9
5 F European descent 2.0 2.5 64.2
6 F African American 0.3 0.4 57.9
10 M African American 2.4 2.6 48.2
11 F African American/Hispanic 0.3 1.3 44.8
13 M African American 3.4 3.6 25.9
14 F European descent 2.6 3.1 27.3
15 M African American 0.9 1.8 43.5
16 F French/English and Chinese 5.9 0.9 22.1
17 F African American 5.1 6.6 14.9
18 F Hispanic Prenatal 0.1 7.1
19 M Biracial 3.3 3.6 9.3
IPD, infantile Pompe disease, ERT, enzyme replacement therapy; ITI, immune tolerance induction; F, female; M, male.
 
Table 2. Demographics of deceased CRIM-negative IPD patients treated with ERT+ITI in the ERT-naive setting
Patient Sex Race/ethnicity Age at diagnosis (mo) Age at initiation of ERT (mo) Age at death (mo)
2 M European descent 2.4 3.6 56.9
7 F African American 3.0 3.4 25.4
8 F Asian 5.5 6.6 30.0
9 F African American 3.2 3.9 15.0
12 M African American 9.8 10.9 29.2
IPD, infantile Pompe disease, ERT, enzyme replacement therapy; ITI, immune tolerance induction; F, female; M, male.
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tions for 13.8 months. Per protocol, due to the development of antibody titers of 6,400, patients 7 and 8 required 
a second cycle of ITI at 35 and 43 weeks from ERT+ITI initiation, respectively (23). Patients 7 and 8 were off  
all ITI medication for 11.6 and 12.4 months, respectively, at their final assessment. Patient 12 received a second 
cycle of ITI at 47 weeks following ERT+ITI initiation due to the development of antibody titers of ≥6,400 and 
was on monthly maintenance rituximab and methotrexate at his final assessment. Patient 15 received a second 
and third cycle of ITI at 79 and 118 weeks following ERT initiation due to the development of antibody titers of  
51,200 and 25,600, respectively. He was on monthly maintenance rituximab and methotrexate at his last assess-
ment. Although planned, the treating physician was unable to get insurance approval for addition of bortezomib 
to the regimen at the time. No ITI regimen was withheld for safety concerns in any of the patients.
Safety measures
B cell recovery. B cell recovery, as measured by normalization of  CD19 percentage, was seen in all but one 
patient (patient 15) (Table 3) in which it was measured. Patient 15 was on rituximab at the final assessment 
prior to the time of  data analysis; hence, B cell recovery was not expected. B cell counts were not assessed 
in patients 6 and 12, and the data on patient 13 was not available.
Vaccination and humoral immune response against vaccines. Seventeen patients (90%) received routine immu-
nizations and were up to date on their childhood immunizations at the time of  data analysis. Patient 17 
was not up to date on vaccines, and vaccination information was not available for patient 16. Titers against 
routine vaccines were performed in 4 patients (patients 3, 11, 14, and 19) after B cell recovery to determine 
if  rituximab administration affected the response to vaccines and were categorized as adequate (immune) or 
inadequate (not immune) based on reference values established by CLIA-certified laboratories. Patient 3 had 
an adequate humoral immune response to measles, mumps, and rubella (MMR); tetanus; Haemophilus influen-
za type b; and pneumococcal serotypes 4, 5, 19F, 23F, 6B, 11A, 7F, 9V, 33F, 1, and 3, while demonstrating an 
inadequate response to hepatitis B and pneumococcal serotypes 8, 9N, 12F, 14, 17F, 20, 22F, 10A, 15B, 19A, 
and 2. Patient 11 had an adequate humoral immune response to MMR, tetanus, and diphtheria. Patient 14 
had an adequate humoral immune response to MMR, varicella, diphtheria, polio, and some pneumococcal 
serotypes and demonstrated a lack of  response to tetanus toxoid, Haemophilus influenza type b, hepatitis B, 
and certain pneumococcal polysaccharide antigens. Patient 19 started ERT+ITI at 3.3 months of  age but had 
received vaccines against diphtheria, tetanus toxoid, pertussis, Haemophilus influenza type b, Pneumococcus, and 
hepatitis B prior to the start of  the ITI regimen. B cell recovery was noted at age 8 months, and an adequate 
humoral immune response against these vaccines was maintained.
Infections around the time of  ITI administration. Most patients safely tolerated ITI administration with-
out infections. However, infections were reported in 4 patients (patients 3, 4, 14, and 16) (Table 3). Two 
patients (patients 3 and 14) experienced central line infections and bacteremia necessitating line removal 
and antibiotic treatment: patient 3 with Enterococcus faecalis, Pseudomonas fluorescens/putida, and Enterococcus 
raffinosus (ITI +2 months) and patient 14 with Klebsiella pneumoniae (ITI +3 months). The absolute neutro-
phil counts (ANCs) around the time of  central line infections in patients 3 and 14 were 6,170/μl and 4,010/
μl, respectively. Patient 4 experienced respiratory syncytial virus infection, and patient 16 suffered an epi-
sode of  aspiration pneumonia and enterovirus/rhinovirus infection around the time of  ITI administration. 
However, neither the ITI regimen nor ERT infusions were withheld for any subject due to infection.
ANC, AST, and ALT data. ANC data were available for 10 patients at baseline and throughout the ITI 
administration. Six of  these ten patients had an ANC of  less than 750/mm3 following the ITI administra-
tion, which was reversible. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) data 
were available at baseline and throughout ITI administration in 11 patients. No increase in AST and ALT 
greater than 3 times their respective baseline values at the time of  ITI administration was noted.
Efficacy of ERT+ITI
Survival. Of  the 19 patients who were treated with ERT+ITI, 14 patients were alive at a median age of  
44.2 months (range 7.1–103.9 months) and 5 patients (patients 2, 7, 8, 9, and 12) were deceased at a 
median age of  29.2 months (range 15.0–56.9 months) at the time of  data analysis (Tables 1 and 2). The 
age at ERT+ITI initiation was significantly earlier in surviving patients (P = 0.03). Although the age at 
diagnosis was also earlier in surviving patients, this was not statistically significant (P = 0.13). In the 14 
surviving patients, the median age at diagnosis and initiation of  ERT+ITI was 2.5 months (range 0.0–5.9 
months) and 2.8 months (range 0.1–6.6 months), respectively. In contrast, for the 5 deceased patients, 
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the median age at diagnosis and initiation of  ERT+ITI was 3.2 months (range 2.4–9.8 months) and 3.9 
months (range 3.4–10.9 months), respectively (Tables 1 and 2). In all 5 deceased patients, the cause of  
death was respiratory failure due to disease progression. Of  the 5 deceased patients, we were able to 
quantify CD19 percentage in 4 (patients 2, 7, 8, and 9), and all demonstrated B cell recovery (Table 3). 
Death occurred at a median time of  22.3 months (range 11.2–53.1 months) after completion of  ITI and 
was unrelated to the administration of  ITI medications.
rhGAA IgG antibody titers. Fifteen (79%) of  nineteen patients either tolerized (did not develop any 
rhGAA IgG antibodies) or maintained low titers (defined as titers of  ≤6,400 throughout the course of  
ERT) following ERT+ITI. Eight (42%) of  these fifteen patients never seroconverted after the imple-
mentation of  ERT+ITI (Table 3) and continued to be antibody negative for a median of  79.5 weeks (n = 
8) following ERT+ITI initiation, with the longest available follow-up antibody titer data at 285 weeks. 
The remaining 7 (37%) of  these 15 patients seroconverted but maintained titers ≤6,400 throughout the 
course of  ERT. Four (21%) patients (patients 10, 12, 14, and 15) broke tolerance to the ERT and had 
antibody titers >6,400. Only 1 (patient 15) of  these 4 patients developed HSAT, with titers peaking at 
51,200 (range: 0–51,200). Three of  these four patients (patients 10, 12, and 14) developed SIT, with 
peak antibody titers of  25,600. Titers in patient 14 peaked at 25,600 (at ITI +22 months) but declined 
to 800 without additional ITI cycles after revision of  rhGAA dosing from 40 mg/kg biweekly to 20 
mg/kg weekly. There was no significant difference in baseline characteristics between the patients who 
broke tolerance to the ERT (patients 10, 12, 14, and 15) as compared with the patients on ERT+ITI 
who maintained low/no titers. Overall, the median rhGAA IgG antibody titers at final assessment for 
the entire cohort was 200 (n = 19; range 0–25,600) (Table 3).
Table 3. Safety measures and immune responses for ERT+ITI in CRIM-negative IPD patients treated in the ERT-naive setting
Patient Rounds of ITI 
administered
B cell recovery (CD19%) Infections Vaccination Antibody titers
Peak titers  
(wk on ERT)
Last titers  
(wk on ERT)
Immune tolerant 
(Yes/No)
CRIM-negative patients treated with ITI (alive at the time of database lock)
1 1 Yes No Yes 1,600 (38) 200 (103) Yes
3 1 Yes Enterococcus faecalis, 
Pseudomonas 
fluorescens/putida, 
Enterococcus raffinosus
Yes 0 0 (281) Yes
4 1 Yes RSV infection Yes 0 0 (285) Yes
5 1 Yes No Yes 0 0 (89) Yes
6 1 Not done No Yes 0 0 (70) Yes
10 1A Yes No Yes 25,600 (199) 25,600 (199) No
11 1 Yes No Yes 0 0 (214) Yes
13 1 NA No Yes 0 0 (11) Yes
14 1 Yes Klebsiella pneumoniae Yes 25,600 (96) 800 (152) No
15 3B Currently on ITI No Yes 51,200 (71) 6,400 (184) No
16 1 Yes Aspiration pneumonia, 
enterovirus/rhinovirus
NA 200 (81) 200 (81) Yes
17 1 Yes No No 200 (3) 200 (32) Yes
18 1 Yes No Yes 0 0 (58) Yes
19 1 Yes No Yes 3,200 (20) 3,200 (24) Yes
Deceased CRIM-negative patients treated with ITI 
2 1 Yes No Yes 0 0 (68) Yes
7 2 Yes No Yes 6,400 (31) 6,400 (59) Yes
8 2 Yes No Yes 6,400 (29) 6,400 (46) Yes
9 1 Yes No Yes 1,600 (39) 800 (46) Yes
12 2C Not done No Yes 25,600 (39) 6,400 (57) Yes
IPD, infantile Pompe disease; ERT, enzyme replacement therapy; ITI, immune tolerance induction. APatient 10 received maintenance rituximab every 2 to 3 
months after the completion of the first cycle. BPatient 15 received monthly maintenance rituximab and methotrexate after the third cycle of ITI. CPatient 
12 received maintenance rituximab and methotrexate until his final assessment.
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Cardiac data. The upper limit of  normal LVMI for infants is 64 g/m2 (≥2 SD higher than the 
age-appropriate normal mean) (31). Baseline LVMI was available on 16 patients, and follow-up LVMI 
was available on 18 patients. Median LVMI at baseline was 248.5 g/m2 (range 65.4–508.0 g/m2) (Table 
4). The median LVMI at final assessment decreased to 76.8 g/m2 (range 48.0–424.2 g/m2) at a median 
time of  59 weeks since ERT+ITI initiation.
Comparison data of the CRIM-negative ERT+ITI group with ERT monotherapy group
The baseline demographics and GAA variant data of  the comparator group can be found in Supplemental 
Table 2. The age at diagnosis in the CRIM-negative ERT monotherapy group was significantly earlier than 
the ERT+ITI group (P = 0.01); however, ERT initiation time was comparable. The median age at ERT 
initiation in the CRIM-negative ERT monotherapy group was 3.3 months as compared with 3.4 months in 
the ERT+ITI group, with no significant statistical difference (P = 0.69). Of  the 20 total GAA variants in the 
ERT monotherapy group, 13 (65%), 6 (30%), and 1 (5%) were nonsense, frameshift, and splice-site variants. 
40% of  the GAA variants were the common African American variant c.2560C>T. The GAA variant data 
and the age at ERT initiation in the CRIM-negative patients in the comparator group (ERT monotherapy) 
were similar to the ERT+ITI group.
Survival
All historical CRIM-negative patients who received ERT monotherapy (comparator group) were deceased 
at a median age of  28.8 months (n = 10; range 14.7–50.2 months) (13). Survival was significantly improved 
for patients in the CRIM-negative ERT+ITI group (P = 0.001) (Figure 1). The age of  the eldest survi-
vor in the ERT monotherapy group was 50.2 months. Six patients in the CRIM-negative ERT+ITI group 
(patients 1, 2, 3, 4, 5, and 6) survived beyond the age of  50.2 months, with the eldest patient in the current 
cohort aged 103.9 months at time of  data analysis.
Figure 1. Kaplan-Meier curve for overall survival of CRIM-negative IPD patients treated with ERT+ITI versus those treated with ERT monotherapy. 
A significant difference in terms of overall survival (P = 0.001) was seen between the CRIM-negative ERT+ITI and the ERT monotherapy group. Death 
occurred in 5 patients in the ERT+ITI group at a median age of 29.2 months (range 15.0–56.9 months). There was a statistically significant difference (P = 
0.03) when comparing age at ERT+ITI initiation, with the living patients starting ERT+ITI earlier, at a median age of 2.8 months, versus deceased patients, 
at a median age of 3.9 months. Survival data of patients with CRIM-negative IPD treated with ERT+ITI were analyzed using the Kaplan-Meier method, 
with 2-tailed P values generated using the log-rank test (43).
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rhGAA IgG antibody titers
All CRIM-negative patients in the ERT monotherapy group (n = 8) and 11 of  19 patients in ERT+ITI 
group developed rhGAA IgG antibody titers. rhGAA IgG antibody titers were significantly lower in 
the ERT+ITI group at week 26 (P < 0.0001), week 52 (P = 0.0004), and week 78 (P = 0.0089) (Figure 
2 and Supplemental Figure 1).
LVMI
The CRIM-negative ERT+ITI group (n = 16; median: 249 g/m2; range: 65–508 g/m2) had an insignifi-
cantly higher median LVMI at baseline as compared with the CRIM-negative ERT monotherapy group (n 
= 10; median: 203 g/m2; range: 89–308 g/m2) (P = 0.39; Figure 3). For the first 26 weeks both groups had 
improvement in LVMI with an insignificant difference (P = 0.8), with a median of  111 g/m2 (n = 16; range: 
55–444 g/m2) and 104 g/m2 (n = 10; range: 57–269 g/m2) for ERT+ITI and ERT monotherapy groups, 
respectively. Subsequently, there was a continued reduction in LVMI in the ERT+ITI group, with a median 
of  88 g/m2 (n = 10; range 59–144 g/m2) at week 52, which was significantly different (P = 0.02) from the 
median of  129 g/m2 (n = 9; range 63–201 g/m2) in the ERT monotherapy group, which worsened.
Discussion
Immune response to ERT is a significant predictor of  therapeutic failure and ultimate death in ERT-treated 
patients with IPD. CRIM-negative cases from across the globe have demonstrated their susceptibility to 
the development of  high rhGAA IgG titers (2, 7, 32, 33). However, unlike other prognostic factors, such 
as degree of  existing damage at baseline, underlying genotype, differences in skeletal muscle fiber-type 
distribution, ACE and ACTN3 genotyping, and defective autophagy, immunogenicity is an avertable com-
plication (34). We previously published our experience of  ITI with methotrexate, rituximab, and IVIG in 
Figure 2. Comparison of longitudinal IgG antibody titers in CRIM-negative IPD patients treated with ERT+ITI tolerized, ERT+ITI nontolerized, or ERT 
monotherapy. High and sustained rhGAA IgG antibody titers (HSAT) defined as titers of ≥51,200 at or beyond 6 months on ERT (shown by a horizontal 
dashed line). ERT+ITI tolerized (n = 15); nontolerized (n = 4); ERT monotherapy (n = 8). CN, CRIM-negative.
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CRIM-negative IPD, in which the oldest patient was 58 months of  age at the time of  publication (22). This 
report of  19 patients is the largest cohort, to our knowledge, of  ERT-treated CRIM-negative patients with 
IPD who completed at least one cycle of  ITI. Data analysis included longitudinal outcomes up to 100.2 
months since initiation of  ERT+ITI. This represents a new cohort of  CRIM-negative IPD patients, with 
an emerging clinical course distinct from the natural history of  CRIM-negative IPD prior to the era of  ITI 
(13). The purpose of  this study was to characterize the long-term safety and efficacy of  ITI in a unique 
cohort of  long-term ERT-treated patients with CRIM-negative IPD.
Safety. Short-course ITI with prophylactic rituximab in the ERT-naive setting conveys a lower risk of  
adverse events than prolonged rituximab administration required in patients who develop HSAT. However, 
rituximab causes B cell suppression, resulting in an increased risk for infection. Therefore, IVIG is admin-
istered to provide some passive immunity. ITI was administered in this cohort without significant safety 
concerns, as evaluated with CD19 percentage as a marker of  B cell recovery; vaccination status/titers 
against vaccines; infections around the time of  ITI administration; and ANC, AST, and ALT data. CD19 
percentage is associated with the degree of  immune suppression and is a useful marker for monitoring the 
status of  immune suppression but not immune tolerance. Of  the patients in whom CD19 percentage was 
assessed, all but one patient who was still receiving ITI medications, demonstrated B cell recovery. These 
data suggest that ERT+ITI patients were able to achieve a B cell recovery after discontinuation of  ITI med-
ications, particularly rituximab, and were not in a constant state of  immune suppression.
Seventeen patients received routine immunizations and were up to date on their childhood immuni-
zations at the time of  data analysis. Titers against the routine vaccines (MMR, tetanus, Haemophilus influ-
enza type b, pneumococcal conjugates, hepatitis B, diphtheria, and varicella) were performed after B cell 
recovery in 4 patients. These patients maintained an adequate humoral immune response against the vac-
cine antigens, except for 2 patients, whose titers against vaccine showed an inadequate humoral immune 
response to hepatitis B, certain serotypes of  Pneumococcus, tetanus toxoid, and Haemophilus influenza type b. 
Based on these data, it would be advisable to monitor vaccination titers after B cell recovery in patients who 
receive ITI (22) and consider additional vaccine boosts.
Although serious infections (i.e., Klebsiella, Pseudomonas, and Enterococcus) were seen in 4 of  19 
patients, neither ITI nor ERT infusions were withheld for any patient. While these infections raise 
some concern about the use of  ITI, bacterial infections were successfully treated with antibiotics and 
temporary removal of  the patients’ central lines. While this does confer some operative anesthesia risk 
due to cardiomyopathy, adherence to anesthesia precautions in Pompe patients resulted in positive 
Figure 3. Comparison of longitudinal LVMI in CRIM-negative IPD patients treated with ERT+ITI versus those treated with ERT monotherapy. Left ven-
tricular mass index (LVMI) continued to decline over time in the ERT+ITI cohort, while increasing after an initial period of reduction in the ERT monothera-
py cohort. The upper limit of normal LVMI is 64 g/m2 (represented by a horizontal dashed line). LVMI values were compared using Wilcoxon/Kruskal-Wallis 
rank-sum test. CN, CRIM-negative.
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Table 4. Efficacy of ERT+ITI in CRIM-negative IPD patients treated in the ERT-naive setting
Patient LVMI (g/m2) Motor status Ventilation status Feeding status
Baseline Final 
assessment 
(wk on ERT)
Baseline Final assessment  
(wk on ERT)
Baseline Final assessment  
(wk on ERT)
Baseline Final 
assessment 
(wk on ERT)
CRIM-negative patients treated with ERT+ITI (alive at time of database lock)
1 NA NA Hypotonia Ambulatory (378) No support No support (378) Oral Oral (378)
3 160.3 70.5 (303) Head lag, severe 
hypotonia, motor delay
Ambulatory, runs but 
clumsy (281)
Oxygen No support (281) NG tube Oral (281)
4 445.8 68.0 (275) Head lag, antigravity 
movements arms > 
legs.
Can move arms against 
gravity (286)
Oxygen and BiPAP at night Invasively ventilated 
(271)
NG tube G tube (271)
5 277.0 65.1 (66) Severe hypotonia, 
floppy baby, no head or 
neck control
Ambulates independently 
(76)
Oxygen No support (76) NG tube Oral (76)
6 409.6 92.3 (53) Axial 
hypotonia,withdraws 
extremities to 
stimulation, weak 
grasp
Sits with support, minimal 
capacity for weight bearing 
on lower extremities (53)
Invasively ventilated Invasively ventilated  
(off ventilator 10–12 
hours a day) (58)
G tube G tube (58)
10 NA 58.4 (228) Hypotonia Ambulatory (199) Invasively ventilated No support (199) TP Oral (199)
11 140.6 61.7 (194) Motor status and 
milestones appropriate 
for her age
Ambulatory (182) No support CPAP with nasal mask 
(199)
Oral Oral (213)
13 508.0 245.0 (11) Hypotonia NA Invasively ventilated Invasively ventilated (13) TP Oral (10)
14 156.7 52.6 (96) Hypotonia Ambulatory, shuffling/foot 
slapping gait (105)
No support No support (105) Oral Oral (105)
15 84.0 57.0 (213) Hypotonia Not ambulatory, can raise 
hands to mouth, holds head 
up, sits with and without 
support (211)
No support Invasively ventilated 
(204)
Oral Oral (204)
16 176.0 48.0 (103) Hypotonia NA BiPAP BiPAP (92) G tube G tube (92)
17 127.5 118.3 (28) Hypotonia Not ambulatory (38) Invasively ventilated Invasively ventilated (38) NG tube G tube (38)
18 65.4 58.8 (48) Head lag, central 
hypotonia
Normal developmental 
milestones (58)
CPAP for a week No support (37) Oral Oral (37)
19 433.1 113.4 (22) Normal symmetric 
bulk, appeared to have 
normal tone
Mild head lag, unable to sit 
unsupported, attempting 
to roll from back to front, 
left to right, but is not 
rolling completely without 
assistance (10)
No support No support (23) Oral G tube (23)
Deceased CRIM-negative patients treated with ERT+ITI
2 NA 257.0 (64) Hypotonia Prop-sit independently, 
sits briefly without hand 
support, rolls from supine 
to side lying, bears weight 
through lower extremities 
in supported standing (80)
Transient ventilation for 
3 days
No support (67) Oral Oral (80)
7 317.2 144.0 (54) Head lag unable to sit 
or roll over
Standing with support (46) Invasively ventilated Oxygen and BiPAP at 
night (46)
NJ tube G tube (46)
8 347.1 108.0 (36) Severe hypotonia, 
antigravity movements 
in arms
Able to move arms against 
gravity, near complete lower 
extremity immobility (50)
Invasively ventilated BiPAP at night (50) NG tube G tube (50)
9 220.0 83.0 (39) Unable to 
independently hold 
hear or sit unsupported
Not able to independently 
hold head or sit 
unsupported (46)
No support Invasive ventilation (46) NG tube GJ tube (46)
12 493.6 424.2 (48) Unable to sit with 
support, severe head 
lag, rolled over at 8 
months
NA Invasively ventilated Invasively ventilated (57) Oral G tube (57)
IPD, infantile Pompe disease; ERT, enzyme replacement therapy; ITI, immune tolerance induction; LVMI, left ventricular mass index; NG tube, nasogastric 
tube; BiPAP, bilevel positive airway pressure; G tube, gastric tube; GJ tube, gastrojejunal tube; TP, transpyloric; CPAP, continuous positive airway pressure; 
NJ tube, nasojejunal tube.
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outcomes. ANC, AST, and ALT data were available for a subset of  patients and demonstrated patient 
tolerance with a reversible decrease in ANC count (6 of  10 patients) and no elevation of  greater than 
3 times the baseline value for AST and ALT.
Five patients died during the course of  follow-up, and none of  these deaths were associated with the 
administration of  ITI. Deceased patients had a later median age at diagnosis and initiation of  ERT+ITI 
(3.2 months and 3.9 months, respectively) compared with earlier diagnosis and treatment for patients who 
were still alive at the completion of  study (2.4 months and 2.6 months, respectively). ERT initiation was 
significantly earlier in surviving patients than patients now deceased (P = 0.02), highlighting the effect 
delayed treatment has on baseline disease severity and the need for timely diagnosis and treatment).
Efficacy. ERT+ITI effectively prevented immunogenicity, reduced cardiomyopathy, and improved sur-
vival for CRIM-negative patients with IPD. LVMI is an easily assessed measure of  cardiomyopathy that has 
been used in pivotal clinical trials to assess efficacy of  alglucosidase alfa (9–11). CRIM-negative patients 
with IPD treated with ERT monotherapy demonstrated initial improvement of  LVMI within the first 6 
months of  treatment, followed by subsequent worsening due to the development of  HSAT (24, 25). In con-
trast, CRIM-negative IPD patients treated with ERT+ITI showed continued improvement of  LVMI, nearly 
reaching the upper limit of  normal (64 g/m2) (31).
As previously reported in our historical cohort of  CRIM-negative IPD patients on ERT monotherapy, all 
were either deceased or invasive ventilation dependent by 27.1 months of  age, and the median age of  death 
was 28.8 months (n = 10; range 14.7–50.2 months) (13). In contrast, in the present cohort of  ERT+ITI–treat-
ed patients, 12 of  19 patients survived beyond 28.8 months (median age of  44.2 months), with a statistically 
significant (P = 001) difference in overall survival in comparison to the historical cohort of  CRIM-negative 
IPD patients on ERT monotherapy. The details in Table 4 show that 7 CRIM-negative patients were ambula-
tory, 8 patients needed no ventilator support, and 10 patients were feeding orally at their final assessment. This 
clearly demonstrates that ERT +ITI has allowed these patients to be ambulatory, free of  invasive ventilation, 
and to behave like CRIM-positive survivors on ERT.
Fifteen patients had low or no rhGAA IgG antibody titers after implementation of  ERT+ITI. Of the 4 
patients who developed titers during the study period, only one patient developed HSAT. Although there are 
3 cases previously reported describing CRIM-negative patients who did not develop HSAT without ITI, one 
patient received omalizumab, an IgG monoclonal antibody that binds to IgE, for a severe allergic reaction 
to alglucosidase alfa; the other sibling pair had a splice site mutation in heterozygosity (35, 36). A role for 
omalizumab in preventing the development of  an IgG response cannot be excluded in this case. Therefore, we 
believe that CRIM-negative ERT monotherapy cases who did not develop HSAT represent a smaller subset 
compared with CRIM-negative cases reported from across the globe with higher susceptibility to the develop-
ment of  high rhGAA IgG titers (2, 7, 32, 33). Currently, there is no way to predict CRIM-negative cases who 
would not develop HSAT/SIT, and this can be a confounding factor while interpreting the efficacy of  this ITI 
protocol. Prior pharmacokinetic studies showed that patients with antibody titers of  ≥12,800 at week 12 had 
an average increase in clearance of  50% from week 1 to week 12 (14). Ultimately, this supports the assump-
tion that development of  antibody titers negatively affects clinical outcomes. Prevention of  an antagonistic 
immune response, as illustrated in the cohort presented here, results in greater efficacy of  ERT, as demon-
strated by improved LVMI and overall survival. Most patients (n = 14) only required one round of  ITI. The 
need for additional rounds of  ITI with the same regimen may partly be due to a Fc-γ receptor polymorphism, 
which reduces the efficacy of  rituximab (37). This requires further investigation and may warrant consider-
ation for use of  other B cell–suppressive agents. Because rituximab is a monoclonal antibody, administering 
IVIG prior to rituximab may saturate the FcRn receptor, thereby precluding recycling of  rituximab and its 
sustained activity (38). Thus, timing of  drug administration is critical and requires further exploration. Never-
theless, based on current data and clinical practices, we recommend rituximab administration prior to IVIG.
Although results from the present cohort provide evidence in support of ERT+ITI for patients with 
CRIM-negative IPD, additional research and protocol adjustments are necessary moving forward. The ITI reg-
imen utilized here targets B and T cells in a nonspecific manner, highlighting the need for development of anti-
gen-specific tolerance induction. Additional challenges with the use of this ITI protocol include the high cost 
and lack of availability of rituximab in certain countries as well as safety issues concerning infection risks due to 
B cell suppression, as mentioned above. The next step toward understanding the immune mechanistic data is to 
study the detailed immune phenotyping of patients that receive the ITI protocol this is being planned.
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Conclusions. Ultimately, longitudinal data from the present cohort demonstrate that treatment with 
ERT+ITI is safe and efficacious, and it allows CRIM-negative IPD patients to continue to maintain clinical 
benefit by reducing or eliminating substantial antibody titers over time with ongoing ERT, as compared with 
CRIM-negative IPD patients treated with ERT monotherapy. ERT+ITI results in tolerance, as evidenced 
by low antibodies to the rhGAA after B cell recovery while maintaining titers against the administered 
vaccines in a majority of  patients. As such, the implementation of  ITI is associated with improved overall 
survival and normalization of  LVMI, which further support our previous experience with CRIM-negative 
IPD patients treated with ERT+ITI (22, 23). With the inclusion of  Pompe disease in the US Recommended 
Uniform Screening Panel and international newborn screening panels, IPD is increasingly identified within 
the newborn period, allowing timely treatment. This is particularly important, as highlighted by our finding 
that patients diagnosed and initiated on ERT+ITI treatment later in time have poorer outcomes due to 
advanced disease. ITI utilizing rituximab, methotrexate, and IVIG should be implemented as standard of  
care in the management of  CRIM-negative patients with IPD.
Methods
Patients. Retrospective data were collected from an international cohort of  patients with IPD, totaling 
217 at the time of  this report, who were enrolled in a Duke IRB-approved protocol (protocol 00001562, 
LDN6709 site 206; ref. 39).
From this cohort, consecutive participants were identified for inclusion in the present study based on the 
following criteria: (a) a confirmed diagnosis of  CRIM-negative IPD (10); (b) initiation of  ITI in the ERT-na-
ive state, with successful completion of  at least one cycle of  ITI with rituximab (4 weekly doses intravenous-
ly), methotrexate (3 doses per week within the first 3 ERT infusions subcutaneously/orally), and/or IVIG 
(monthly) (Supplemental Figure 2) (23); (c) ERT with alglucosidase alfa at a cumulative dose of  20–40 mg/kg 
weekly or biweekly; and (d) at least 6 months of  follow-up data since initiation of  ERT+ITI.
A cohort of  CRIM-negative IPD patients who participated in the original clinical trials of  rhGAA, pri-
or to the establishment of  ITI as standard of  care, served as a comparison group (10, 11, 40, 41). A total of  
10 CRIM-negative IPD patients treated with ERT monotherapy were identified, and their overall survival 
data were reviewed along with their rhGAA IgG antibody titers and LVMI at baseline, week 26, and week 
52 on ERT, for comparison with CRIM-negative IPD patients on ERT+ITI.
Data collection. Relevant clinical data, including GAA variants, CRIM status, and rhGAA IgG antibody titers 
(determined by Genzyme) were extracted from medical records of qualifying patients (10, 11, 28, 42). Longitu-
dinal data, provided by the onsite local treating physician, were collected with regard to rhGAA IgG antibodies, 
LVMI, motor status, pulmonary status (ventilator use), feeding status (oral feeds, gastrostomy tube, nasogastric 
tube) at baseline and follow-up as possible. For deceased patients, age and cause of death were collected. LVMI 
was measured by 2D, M-mode, and Doppler echocardiography. ITI safety was assessed by measuring CD19 
percentage as a marker of B cell recovery. Flow cytometry was used to assess CD19 percentage using standard 
methods. Vaccination status and antibody response to vaccines were collected as markers of B cell recovery and 
to ascertain if  administration of rituximab resulted in loss of protective immunity. ITI safety was also assessed 
by collecting data on infections around the time of ITI administration and ANC, AST, and ALT levels before 
and after completion of ITI. AST and ALT values 3 times above baseline and ANC values of less than 750/
mm3 were considered an adverse event related to ITI. Data collection continued until April 2016 or until at least 
6 months had passed since initiation of ERT+ITI, at which time the database was locked for analysis.
Statistics. Survival data for patients with CRIM-negative IPD treated with ERT+ITI were analyzed using 
the Kaplan-Meier method, with 2-tailed P values generated using the log-rank test (43), and compared to a 
historical cohort of  CRIM-negative patients with IPD on ERT monotherapy (23). IgG antibody titers and 
LVMI values were compared using Wilcoxon/Kruskal-Wallis rank-sum test (2, 12). Other nonparametric 
variables were analyzed using Kruskal-Wallis Rank sum test. Analyses were performed with STATA version 
14.2 (StataCorp LP). Descriptive data are presented as medians due to the limited sample size.
Study approval. This study was conducted according to the principles of  the Declaration of  Hel-
sinki and approved by the Duke University Medical Center IRB (protocol 00001562). Patients were 
included in the study after provision of  written informed consent by their legally authorized represen-
tative. One patient (patient 1) was enrolled after approval from the IRB or ethics committee approval at 
Soroka University Medical Center. All the other patients were enrolled in the Duke University Medical 
Center IRB (protocol 00001562).
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